Finanzen von Lisata Therapeutics Inc (LSTA)LSTALisata Therapeutics Inc

Lisata Therapeutics Inc (LSTA) generates its revenue primarily from PCT Segment, which accounts for 100.0% of total sales, equivalent to $7.92M. Understanding this concentration is critical for investors evaluating how LSTA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Lisata Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -99.89%, provide a clear picture of how effectively LSTA converts its operational activities into shareholder value.

In the context of the broader market, LSTA competes directly with industry leaders such as HIND and AEON. With a market capitalization of $14.15M, it holds a significant position in the sector. When comparing efficiency, LSTA's gross margin of N/A stands against HIND's 33.57% and AEON's N/A. Such benchmarking helps identify whether Lisata Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Lisata has reported fluctuating revenues with a total revenue of $1 million in Q4 2024, but it has also faced substantial net losses, including a net income loss of $4.49 million in Q1 2026. The gross margin is currently at 100% for the last two quarters where revenue was recorded, but overall financial health remains precarious.